Capacity Tracker

Expected milestone: Q4 2026–Q1 2027 — first five workshops' trial production (company guidance)

Project-level construction; trial production, commercial production and product-line readiness are not confirmed. Review 2026-10-09: Trial guidance remains Q4 2026–Q1 2027 for first five workshops; no product mapping or commercial production confirmation.

Whole phase-one total. Includes 290 tonnes/year protected amino acids, 2,500 coupling reagents and 800 protection reagents. Components are subsets, not additional projects or quantities.

August 25 guidance is subject to construction progress. Window covers the first five of ten workshops, without product allocation; full-project startup unresolved.

Module One reported operational September 15, 2026; utilization and customer-specific qualification undisclosed. Module Two remains proposed. Review 2026-10-09: Recovered company original: Module One operational at 7,000 L. Earlier 6,370 L unreconciled. Module Two up to 18,000 L remains proposed with no startup date.

Module One: 750 L SPPS + 6,250 L LPPS. Earlier 6,370 L specification remains unreconciled. Module Two up to 18,000 L is prospective, not additional operating capacity. Reactor volume is not annual API output.

Module Two startup undisclosed. Engineered >100 kg/year claim has unresolved module/scope and is not treated as demonstrated output.

Company reported engineering/preconstruction and consent to establish; peptide commissioning unverified. Review 2026-10-09: Site groundbreaking does not prove peptide-fragment construction or commissioning. Preserve planned peptide status.

Peptide fragments/intermediates prioritized; peptide-specific capacity undisclosed. Mixed-project investment is not peptide capacity.

August 3 management guidance concerns prospective commercialization around end-FY2029–FY2030, not a verified commissioning date.

Company website reports construction; its publication date is undisclosed.

Peptide-specific capacity undisclosed. Separately commissioned Unit III and its 16 kL disclosure are excluded from this entry.

Laboratory expansion announced; operations not verified.

Supporting peptide development space, not commercial API manufacturing volume or annual output.

Expansion announced; commissioning not verified. Review 2026-10-09: Protected amino-acid expansion remains relevant; latest report supplies no quantitative product capacity or verified startup.

Protected-amino-acid capacity not quantified.

Expected milestone: Early 2028 — company editorial indexed text; full-page confirmation pending

September 22 company groundbreaking; commissioning unverified. Acquisition completed in August and adds no new physical capacity. Review 2026-10-09: September 28 company editorial indexed text gives early-2028 go-live, later than June end-2027. Full-page access failed: qualified timing update only. Preserve USD118.96m / USD121.9m and later >USD200m scope differences; same 68,000 sq ft project and acquisition history.

One expansion originated by AmbioPharm. Floor area is not peptide output capacity. Investment disclosures have unresolved scope/budget differences.

June 16 state guidance; meaning of online is unspecified and was not reconfirmed in September. No exact startup date established. Earlier end-2027 guidance preserved as history; no exact commercial-production date.

Company reports commercial GMP manufacturing and ramp-up; full utilization not established. Review 2026-10-09: July company update confirms commercial GMP manufacturing/ramp; April inauguration is a separate milestone.

Peptide-only quantitative capacity undisclosed.

Company-reported construction; project commissioning and final permitting unverified.

June EIA describes 10 tonnes/year added after completion; October 2025 announcement describes >10 tonnes/year total with existing lines. Scope unresolved; neither is operating output. Other ramping workshops are not this project.

Construction/retrofit reported; commissioning and API-grade scope unverified.

120 kg/year semaglutide + 20 kg/year tirzepatide, planned. Non-peptide environmental acceptance does not establish peptide commissioning.

Historical May–July 2026 construction timetable is not a startup date. No peptide startup verified through October 7.

Company manufacturing section reports commissioned as of June 30; introductory equipment-commissioning wording conflicts. Review 2026-10-09: Qiantang commissioned as of June 30 per September filing; actual output unquantified. Rocklin end-2026 up-to-300 kg/year target and new Qiantang phase-I property project are separate proposals.

Several tonnes/year is unquantified and not actual output. Up to 100 kg/batch is a separate capability. 3,000 L reactors are individual equipment scale, not a summed site volume. Rocklin and the separate proposed Qiantang phase I are excluded.

Expected milestone: 2030 — company production-start guidance

Planned strategic collaboration; construction/operation not confirmed. Review 2026-10-09: Sisslerfeld customer-backed first-phase production target 2030; no annual output quantity.

Peptide-specific quantitative capacity undisclosed; investment is not output.

Company expectation, not a guaranteed or exact commissioning date.

Dedicated arrangement announced; completed scale-up and operating output unverified.

Arene owns/operates the capacity; it is not directly owned HRV capacity. Peptide-specific quantity and precise site unresolved.

Earlier March–May 2027 estimate remains unconfirmed; no verified startup date.

Manufacturing details pending; no verified peptide commissioning milestone by October 7.

Peptide-specific quantitative capacity undisclosed. Broader small-molecule 230 kL is excluded.

CPHI publicity promised further details; this is not a verified plant startup date.

Environmental approval received; commissioning/operation unverified.

280 kg/year fermentation-route semaglutide, 60 SPPS semaglutide, 40 tirzepatide. Tirzepatide route unresolved. Prospective capacity, not demonstrated output.

Startup depends on completion and operation of external industrial wastewater infrastructure; no date established.

Operating project reported by company; design capacity is not actual production or unrestricted merchant availability.

Rounded July 5.8-tonne claim and earlier Workshop 601 annual figures remain distinct/unreconciled. Historical 4.7% utilization denominator/period unresolved; no spare-capacity calculation.

Planned project; approvals progressing. Construction/operation of peptide supports not verified.

Peptide solid-phase synthesis supports/resins included; peptide-specific capacity undisclosed. Whole-park 16,400 tonnes/year and investment are excluded. August resin scale-up is not established as Pucheng production.

May 20 company expectation of phased completion/production over approximately two years concerns the park; peptide-line startup undisclosed.

Aggregate baseline commissioned according to company. Separate Tianjin mixed-TIDES investment is under construction, not operational; relationship to baseline unresolved. Review 2026-10-09: Commissioned >45,000 L and separate >22.5 tonnes/year company claim retained; ~69,000 L is future total target reaffirmed August, not an incremental 24,000 L addition.

Separate >22.5 tonnes/year capability claim is not actual output or another project. ~69,000 L year-end target is a future total. Tianjin peptide-specific capacity undisclosed. Grouped to prevent overlapping entry/quantity counts.

~69,000 L by end-2026 is a capacity target, not a verified startup date. Tianjin project startup undisclosed.

Company-announced expansion; new construction commencement unverified.

>70,000 L SPPS and >30 tonnes/year are prospective company targets only. Earlier capacity figures/timelines remain unreconciled; target/API-grade scope uncertain. No additive building 2–4 entries.

Five-year plan is not an exact commissioning/startup date.

Line 3 construction reported in March; later startup remains unverified. Line 4 remains planned, not verified under construction.

Reliable line-specific quantitative capacity undisclosed. Conditional full-load/batch claims excluded. API qualification, products and parcel scope unresolved.

Line 3 end-April target elapsed without verified startup. Line 4 end-2026 remains company guidance, not an established startup date.

Initial engineering complete; construction commencement unverified through October 7.

Commercial-scale liquid-phase peptide manufacturing planned. Broader 140,000 L / USD120m figures are not peptide-specific. Peptide quantity and annual output undisclosed.

Late-2026 groundbreaking guidance is not verified commencement or an operational startup date.

Expected milestone: 2027 — company target for API-site opening

API site target opening 2027. Separate Advanced Therapies site opened May 2026. Investment spans sites and mixed API products; no peptide-specific quantity.

Company milestone/target; exact production eligibility or output not inferred.

Expansion began making medicines in 2023, inaugurated 2024. SPPS fragments plus continuous LPPS; no annual peptide capacity disclosed.

Company milestone/target; exact production eligibility or output not inferred.

Expected milestone: 2029 — company fully-operational target

Multi-product API including GLP-1 plus packaging; expected fully operational 2029. Original >DKK42bn, latest DKK49.6bn whole-project budget, not capacity. Distinct earlier fermentation upgrade not additive.

Company milestone/target; exact production eligibility or output not inferred.

Aggregate >100,000 L SPPS at end-2025. Future 130,000 L target undated. Chinese site quantities not allocated; Singapore TIDES Q2 2028 target. Children are not additional public groups.

Company milestone/target; exact production eligibility or output not inferred.

Expected milestone: 2028 — company target

25,000 L disclosed addition; >42,000 L future site total in 2028. Not additive to each other. Separate from CAP-2026-008 development laboratory floor area.

Company milestone/target; exact production eligibility or output not inferred.

Started production December 2024; target utilization achieved H1 2026. Contract-backed facility; no inference of spare capacity or annual output. EUR100m investment/order value not physical capacity.

Company milestone/target; exact production eligibility or output not inferred.

Expected milestone: 2027 — company ramp target

Construction complete; commissioning ongoing as of H1 results. Ramp target 2027. Relative doubling not annual output; supported by customer contract, no exclusivity inferred.

Company milestone/target; exact production eligibility or output not inferred.

Company reported expanded SPPS operational by March 12, 2026; H2 2026 ramp target. Relative doubling not annual output; exact startup date undisclosed.

Company milestone/target; exact production eligibility or output not inferred.